The healthcare product provider has promoted Lizzie Lee to lead portfolio development and market research at its corporate venturing unit.

IP Group was among the investors for UPenn-founded cancer immunotherapy developer Carisma Therapeutics, which has now raised nearly $109m altogether.

The endocrine disease drug developer completed a series B round that included $125m from former parent company Ascendis.

Sanofi Ventures contributed to a series C round for Dice Molecules, which is advancing a potential psoriasis treatment.

Livzon Pharmaceutical, Merck & Co and AbbVie helped the immuno-oncology therapy developer take its overall funding to $109m.

Taiho Ventures returned for a $72m series B round closed by Werewolf Therapeutics, which is now set to advance two lead oncology assets through phase 1 trials.

Bristol Myers Squibb, Eli Lilly and Novo are among the limited partners in the pharmaceutical-focused venture firm's BGV IV fund, which has reached its final close.

UPMC Enterprise has returned for a $72m series B round raised by Werewolf Therapeutics, which is now set to advance two lead assets through phase 1 trials.

Osage University Partners has contributed to an $80m round for Dice Molecules, which is advancing Stanford University research and is also backed by Sanofi and Alexandria.

Novo helped the cardiac pump developer CorWave secure series C funding to increase its total funding to over $95m.